Dr. Zejnullahu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
505 Parnassus Ave
San Francisco, CA 94122- Is this information wrong?
Education & Training
- University of California (San Francisco)Residency, Internal Medicine, 2014 - 2017
- University of Massachusetts Medical School
Certifications & Licensure
- CA State Medical License 2016 - 2025
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 3560 citationsMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland
Science. 2007-05-18 - 480 citationsActivation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Taroh Satoh, Federico Cappuzzo
Science Translational Medicine. 2011-09-07 - 564 citationsPF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to GefitinibJeffrey A. Engelman, Kreshnik Zejnullahu, Christopher Michael Gale, Eugene Lifshits, Gonzales Andrea
Cancer Research. 2007-12-15
Other Languages
- Spanish
Hospital Affiliations
- California Pacific Medical Center-Davies CampusSan Francisco, California
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: